BridgeBio Pharma BBIO
NASDAQ BBIO
$79.54 +0.87 (+1.11%)
At close: Nov 11, 2026 · 4:00 PM EST

BridgeBio Pharma (BBIO) Long-Term Debt Issuances (2018 - 2026)

Updated

BridgeBio Pharma (BBIO) reported Long-Term Debt Issuances of $632.5 million for Q1 2026, up 10.0% from $575 million a year earlier.

Analysis

BridgeBio Pharma (BBIO) Long-Term Debt Issuances (2018 - 2026) Analysis & Trends

For FY2025, BridgeBio Pharma posted Long-Term Debt Issuances of $575 million, up 27.8% from FY2024.

  • Long-Term Debt Issuances has a five-year compound annual growth rate of 0.9% (FY2020 to FY2025).
  • By year, Long-Term Debt Issuances came in at $450 million in FY2024 and $1.2 billion in FY2021 (+118.9%).
  • The Q1 2026 figure ranks as the highest quarterly Long-Term Debt Issuances since Q1 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Issuance (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 9.98 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 BridgeBio Pharma 15.42 Bn 11.64 Bn 332.72 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 632.50 Mn
Mar 31, 2025 575.00 Mn
Mar 31, 2024 450.00 Mn
Dec 31, 2021 431.30 Mn
Jun 30, 2021 25.00 Mn
Mar 31, 2021 747.50 Mn
Mar 31, 2020 550.00 Mn
Dec 31, 2019 17.15 Mn
Dec 31, 2018 19.85 Mn
Sep 30, 2018 -20.84 Mn
API Access

BridgeBio Pharma Long-Term Debt Issuances API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-issuances&ticker=BBIO&period=max&api_key=YOUR_API_KEY